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This randomised multicentre phase II study was conducted to investigate the activity and safety of two oral fluoropyrimidines,
capecitabine or S-1, in elderly patients with advanced gastric cancer (AGC). Elderly (X65 years) chemo-naive patients with AGC
were randomly assigned to receive capecitabine 1250mgm
 2 two times daily on days 1–14 every 3 weeks or S-1 40–60mg two
times daily according to body surface area on days 1–28 every 6 weeks. Ninety-six patients were enrolled and 91 patients were
randomised to capecitabine (N¼46) or S-1 (N¼45). Overall response rate, the primary end point, was 27.2% (95% CI, 14.1–40.4,
12 of 44 assessable patients) with capecitabine and 28.9% (95% CI, 15.6–42.1, 13 of 45) with S-1. Median times to progression and
overall survival in the capecitabine arm (4.7 and 9.5 months, respectively) were similar to those in the S-1 arm (4.2 and 8.2 months,
respectively). The incidence of grade 3–4 granulocytopenia was 6.8% with capecitabine and 4.8% with S-1. Grade 3–4
nonhaematologic toxicities were: asthenia (9.1% with capecitabine vs 7.1% with S-1), anorexia (6.8 vs 9.5%), diarrhoea (2.3 vs 0%),
and hand–foot syndrome (6.8 vs 0%). Both capecitabine and S-1 monotherapies were active and tolerable as first-line treatment for
elderly patients with AGC.
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Stomach cancer is the fourth most frequent malignant disease and
the second most common cause of cancer-related deaths in the
world (Parkin et al, 2005; Ries et al, 2007). Although the number of
deaths from gastric cancer has declined over the past decades as a
result of screening endoscopy, the elderly are primarily affected by
the disease with most gastric cancer-related deaths occurring in
patients aged 65 years or older (Ries et al, 2007).
Systemic chemotherapy improves the quantity and quality of life
in patients with gastric cancer when compared with best supportive
care alone (Murad et al, 1993; Pyrhonen et al, 1995; Glimelius et al,
1997). Various chemotherapeutic agents are used for the treatment
of advanced gastric cancer (AGC). Some are used as single agents,
others as part of combination regimens. 5-Fluorouracil (5-FU) has
been the backbone of most regimens for AGC for several decades,
and is used most commonly in combination with a platinum with or
without an anthracycline or taxane (Kim et al, 1993; Webb et al,
1997; Waters et al, 1999; Vanhoefer et al, 2000; Van Cutsem et al,
2006). However, elderly cancer patients often present with
concomitant co-morbidities and age-associated physiologic pro-
blems, such as impaired organ function and functional changes that
make the selection of optimal treatment difficult (Repetto and
Balducci, 2002; Lichtman et al, 2007b). There is also uncertainty
about the use of systemic palliative chemotherapy in elderly patients
because of under-representation of this age group in clinical trials
(Murthy et al, 2002; Lewis et al,2 0 0 3 ;L i c h t m a net al, 2007a).
Capecitabine is an oral fluoropyrimidine carbamate, which is
enzymatically converted to 5-FU in several steps following
absorption from the gastrointestinal tract. The final step involves
the enzyme thymidine phosphorylase, which is found at much
higher levels in gastric cancers than in normal tissue, enabling the
active drug 5-FU to be generated preferentially at the tumour site
(Miwa et al, 1998). The efficacy and safety of the standard 3-weekly
intermittent regimen of capecitabine for AGC has been demon-
strated in a Korean study including 55 chemo-naive patients
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s(Hong et al, 2004). The overall response rate (ORR) was 34% with
a median overall survival (OS) of 9.5 months with a favourable
safety profile. More recently, two randomised phase III trials in
patients with AGC have been completed. The first multinational
study showed that capecitabine/cisplatin was noninferior to 5-FU/
cisplatin in terms of progression-free survival (Kang et al, 2006).
The second trial (REAL 2), which was performed in the UK and
Australia, demonstrated that capecitabine can replace 5-FU and
oxaliplatin can replace cisplatin in triple combinations used for the
treatment of advanced esophagogastric cancer (Cunningham et al,
2008). Capecitabine has since received approval for use in AGC
on the basis of these trials.
S-1 is a novel oral fluoropyrimidine consisting of a 5-FU
prodrug, tegafur, and the dihydropyrimidine dehydrogenase
inhibitor, 5-chloro-2,4-dihydroxypyridine and the orotate phos-
phoribosyl transferase inhibitor, potassium oxonate, which
suppresses the gastrointestinal toxicity of tegafur (Maehara,
2003). In two phase II studies in patients with AGC conducted in
Japan, 80mgm
 2 of S-1 daily for 4 weeks followed by a 2-week rest
period showed high ORRs of 49% (25 of 51) and 44% (19 of 43),
respectively, with median OS of 8.3 and 6.8 months, respectively
(Sakata et al, 1998; Koizumi et al, 2000). By virtue of their oral
formulations, promising efficacy, and favourable toxicity profiles,
capecitabine and S-1 may be particularly attractive for elderly
cancer patients.
This phase II trial (NCT00278863) was conducted to evaluate the
efficacy, safety, and feasibility of capecitabine or S-1 in elderly
patients with previously untreated AGC and to assess the relative
advantages of these agents in the treatment of AGC.
MATERIALS AND METHODS
Patients
Elderly patients (agedX65 years) with advanced, unresectable,
histologically confirmed adenocarcinoma of the stomach or
gastroesophageal junction were eligible if they met the following
inclusion criteria: ECOG performance status 0–2; measurable
disease based on RECIST criteria; no previous chemotherapy
except adjuvant chemotherapy completed at least 12 months
before enrollment; an estimated life expectancy of more than 3
months; ability for adequate oral intake; adequate bone marrow
function, defined as leukocyte count X4000ml
 1, absolute
neutrophil count (ANC) X1500ml
 1, haemoglobin X9.0gdl
 1,
and platelets X100000ml
 1; adequate renal and hepatic function,
defined as serum creatinine o1.5mgdl
 1, bilirubin o1.5mgdl
 1,
and serum transaminase o3 times the upper normal limit (UNL)
(o5 times UNL for patients with liver metastases); and written
informed consent. Patients were excluded if they had brain
metastases, significant gastrointestinal bleeding, a serious co-
morbid condition, concomitant use of any drugs, which had a
potential interaction with S-1 (flucytosine, allopurinol, warfarin,
and phenytoin), or inability to comply with the requirements of
the protocol. This study was initially approved by the Institutional
Review Board (IRB) of the Asan Medical Center and later by all
IRBs responsible for the participating centres.
Study design and randomisation
This study was an open-label, multicentre, randomised phase II
trial with two treatment arms. Random assignment (1:1 ratio) was
centralised and performed by the Coordination Center for Clinical
Trials on Gastrointestinal Cancer at the Asan Medical Center,
Seoul, Korea. Randomisation was stratified by age (p75 years vs
475 years), performance status (0–1 vs 2), and prior gastrectomy
(yes vs no).
Treatment dose and schedule
Patients were randomly assigned to receive either capecitabine or
S-1 as recommended in the package insert. Capecitabine
2500mgm
 2 was administered orally in two divided doses daily
on days 1–14 of a 21-day cycle. The dosage of capecitabine
was adjusted or interrupted for treatment-related adverse events
of grade 2 or worse based on a previously defined algorithm
(Blum et al, 1999). S-1 was given orally two times daily for 28 days,
followed by 14 days’ rest. Three dosage levels of S-1 were defined
according to body surface area (BSA) as follows: BSA less than
1.25m
2, 40mg two times daily; BSA, 1.25 to 1.5m
2,5 0 m g
two times daily; and BSA more than 1.5m
2, 60mg two times
daily. S-1 was temporarily discontinued and the same dose was
retried if patients experienced grade 2 nonhaematologic toxicities,
grade 3 thrombocytopenia, or uncomplicated grade 4 neutropenia.
If the toxicity recurred or grade 3 nonhaematologic toxicities,
grade 4 thrombocytopenia, or febrile neutropenia occurred,
S-1 was interrupted until the toxicity subsided to grade 1 or less.
The BSA-adjusted S-1 dose was then reduced from 120 to
100mgday
 1, from 100 to 80mgday
 1, or from 80 to 50mgday
 1.
The subsequent chemotherapy cycle was started only if the
ANC recovered to X1500ml
 1 and the platelet count reached
X100000ml
 1, and nonhaematologic toxicity recovered to grade 1
or less. A treatment delay of up to 3 weeks was permitted without
dose reduction. If the ANC was X1000ml
 1 but o1500ml
 1 and
the platelet count was X75000ml
 1 but o100000ml
 1 on the
scheduled day 1 of the next cycle after a 1-week delay, treatment
could be started with a 25% reduced dose of capecitabine or at the
next lowest dose level for S-1. Each treatment was continued until
the occurrence of disease progression, unacceptable toxicities,
or patient’s refusal to continue.
Pretreatment and on-treatment evaluation
No more than 2 weeks before study entry, patients underwent the
following evaluations: medical history; complete physical exam-
ination including ECOG performance status; complete blood
count, serum chemistry with electrolyte and coagulation battery;
urinalysis; chest X-ray; electrocardiogram; and computed tomo-
graphy (CT) of the abdomen and pelvis (CT of chest or neck was
also performed if indicated). Charlson comorbidity index (CCI)
was prospectively calculated before treatment (Charlson et al,
1987). Other investigations, for example, bone scan or bone X-ray,
were performed if clinically indicated to document metastatic
disease.
All patients were reviewed before the commencement of each
cycle of chemotherapy. Complete and differential blood counts and
serum chemistry were performed before each 21-day cycle for
patients receiving capecitabine and before each 42-day cycle for
patients receiving S-1. More frequent reviews and monitoring were
undertaken if clinically indicated.
Compliance with study medications was monitored by ques-
tioning patients and counting their remaining pills at each visit.
The ratio of the actual dose taken to the prescribed dose was
calculated and used to calculate relative dose intensity.
All patients completed a quality-of-life (QOL) questionnaire
(EORTC QLQ-C30, QLQ-STO22 Korean version) within 14 days
before registration, with each even-numbered chemotherapy cycle
for patients receiving capecitabine or each chemotherapy cycle for
patients receiving S-1, at the end of the study treatment, and every
2 months thereafter. Results on QOL are to be reported in a
separate publication.
Response and toxicity criteria
Tumour response was assessed every two cycles in the capecitabine
arm and every cycle for S-1 according to the RECIST criteria. At
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seach of these assessments, the same imaging technique was used as
was employed at baseline. National Cancer Institute Common
Toxicity Criteria, version 2.0, were used to assess toxicity.
Radiographs of all eligible patients were also reviewed extra-
murally to confirm investigator-designated responses.
Statistical analysis
The primary end point was ORR as assessed by external
independent review, which was analysed on both an intention-
to-treat (ITT, all eligible patients who were randomly assigned)
and per-protocol (PP, treated patients eligible and assessable for
response without major protocol violations) basis. Patients were
considered assessable for response if they had received at least two
cycles of chemotherapy in the capecitabine arm and one cycle in
the S-1 arm and had had at least one follow-up tumour assessment.
However, patients were also considered assessable if they had
received less than the predefined number of cycle(s) of
chemotherapy due to rapid tumour progression.
Simon’s optimal two-stage design was used for both treatment
arms to allow early termination of inactive arm(s). To test the null
hypothesis P0p0.1 vs the alternative hypothesis P1X0.25, the first
stage required at least three or more patients out of 18 to have a
confirmed response with a¼0.05 and b¼0.2 before proceeding to
the second stage. In the second stage, 25 assessable patients could
be added and if a total of eight or more patients achieved a
confirmed response, then the primary end point would have been
met.
The secondary end points were time-to-progression (TTP),
time-to-treatment failure (TTF, including progression, death,
or withdrawal), and OS. Kaplan–Meier estimates and the Cox
proportional hazard model were used in the analysis of time-event
variables. Comparison of the distribution of discrete variables in
the two treatment arms were performed by the w
2 test or Fisher’s
exact test when appropriate, and further evaluated by logistic
regression analysis. For continuous variables, the Mann–Whitney
U-test for nonparametric data was used. All tests were two sided
and a P-valueo0.05 was considered as statistically significant.
SPSS for Windows version 13.0 (SPSS Inc., Chicago, IL, USA) was
used for statistical analyses.
RESULTS
Patient characteristics
From October 2004 to April 2006, 96 patients from nine centres in
Korea were enrolled; 49 were randomly assigned to receive
capecitabine and 47 to S-1. As shown in Figure 1, five patients
were ineligible and were excluded from the analysis. Therefore,
the ITT population contained 91 patients. Two patients in the
capecitabine arm withdrew consent without study treatment and
were excluded from the PP analysis. The baseline characteristics
were well balanced between the two treatment arms (Table 1). The
median age of patients was 71 years (range, 65–82 years) and the
CCI was 1 or more in 37% of patients.
Exposure to study medication
In total, 240 cycles of capecitabine and 144 cycles of S-1 were
administered, with a median of five cycles (range, 1–22) in the
capecitabine arm and two cycles (range, 1–14) in the S-1 arm.
Thirty-four patients in the S-1 arm received 60mg two times daily
and the remaining 11 patients received 50mg two times daily. The
median relative dose intensity per patient was 87.6% (range, 32.3–
102.4%) for capecitabine and 96.3% (range, 16.1–102.5%) for S-1
(P¼0.003). Although the relative dose intensity for S-1 remained
stable, there was a steady decrease in relative dose intensity for
capecitabine during treatment (Figure 2). There were more dose
reductions (27.5% of cycles and 36.4% of patients) and dose delays
(12.7% of cycles and 31.8% of patients) with capecitabine than with
S-1 (2.1% of cycles and 11.4% of patients for dose reductions, and
7.6% of cycles and 13.3% of patients for dose delays). Hand–foot
syndrome (16.9% of cycles) and neutropenia (4.7% of cycles) were
96 elderly patients randomly assigned
Capecitabine (n=49) S-1 (n=47)
Not eligible (n=3) Not eligible (n=2)
Not measurable (n=2) Not measurable (n=1)
Outdated baseline CT (n=1) Poor performance  (n=1)
Recieved capecitabine  (n=44)
Did not recieve capecitabine (n=2): 
         Consent withdrawl
Available for response (n=44) Available for response (n=45)
Response not evaluable (n=4): Response not evaluable (n=4)
Early death due to ICH (n=1)
Treatment refusal before response 
         assessment (n=3)
Treatment refusal before response 
         assessment (n=3)
Off-study due to toxicity (n=1)
Recieved S-1 (n=45)
Figure 1 CONSORT diagram.
Table 1 Patient characteristics at baseline (ITT population)
Capecitabine S-1
No. (%) No. (%)
No. of patients 46 45
Age (years)
Median 71 71
Range 66–78 65–82
ECOG performance status
0 7 (15.2) 10 (22.2)
1 35 (76.1) 33 (73.3)
2 4 (8.7) 2 (4.4)
Gender
Male 30 (65.2) 37 (82.2)
Female 16 (34.8) 8 (17.8)
Body surface area (m
2)
Median 1.50 1.60
Range 1.24–1.91 1.26–2.05
Charlson comorbidity index
0 28 (60.9) 29 (64.4)
1 17 (40.0) 12 (26.7)
2 0 3 (6.7)
3–4 1 (2.2) 1 (2.2)
Prior gastrectomy 10 (21.7) 10 (22.2)
Adjuvant chemotherapy 2 (4.3) 4 (8.9)
Elevated alkaline phosphatase 11 (23.9) 12 (26.7)
Metastatic sites
Liver 28 (60.9) 22 (48.9)
Peritoneum 8 (17.4) 13 (28.9)
Bone 1 (2.2) 0
Lymph node 31 (67.4) 29 (64.4)
No. of metastatic organs
1 23 (50.0) 24 (53.3)
2 17 (37.0) 13 (28.9)
X3 6 (13.0) 8 (17.8)
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sthe most frequent reasons for dose reductions in the capecitabine
arm. These toxicities did not result in dose reduction in the
S-1 arm.
The main reason for discontinuing study treatment was disease
progression (64% of patients in the capecitabine arm and 71% of
patients in the S-1 arm). Other reasons included patient refusal
(22.7% for capecitabine and 13.3% for S-1), death (4.5 and 4.4%,
respectively), and other concomitant illnesses not associated with
study treatment (6.8 and 6.6%, respectively). Only one patient in
each treatment group was taken off study treatment because of
intolerable treatment-related toxicities: recurrent grade 2 vomiting
in the capecitabine arm, and grade 3 abdominal pain in the S-1
arm.
Treatment response
The ORR for both the ITT and PP populations are shown in
Table 2. Both treatments met the primary end point of this study.
The confirmed ORR for the ITT population was 26.1% for
capecitabine (95% CI, 13.4–38.8) and 28.9% for S-1 (95% CI,
15.6–42.1). ORR for the PP population was 27.2% for capecitabine
(95% CI, 14.1–40.4) and 28.9% for S-1 (95% CI, 15.6–42.1). The
median duration of response in the ITT population was 6.3 months
for capecitabine (95% CI, 5.46–7.14) and 8.5 months for S-1 (95%
CI, 5.70–11.26), with a hazard ratio (capecitabine/S-1) of 1.3 (95%
CI, 0.54–3.20). The reason that patients were not assessed for
efficacy are shown in Figure 1. Logistic regression analysis revealed
that none of the potential prognostic factors were statistically
significant predictive factors for overall response (Table 3).
Secondary end points
At the last data cutoff date, 15 May 2007, the median follow-up
duration was 21.9 months in the capecitabine arm (95% CI, 19.4–
24.5) and 21.7 months in the S-1 arm (95% CI, 18.4–25.0). At this
time, 73 of the 91 patients had died. Disease progression was the
major cause of death and accounted for 95.8% of patient deaths in
both treatment groups. Two patients in the capecitabine arm died
from non-cancer-related causes (intracranial haemorrhage, n¼1;
sudden cardiac death, n¼1) both of which had no direct causal
relationship with study medication. The cause of death in one
patient allocated to S-1 was unclear.
The median TTP was 4.7 months for capecitabine (95% CI,
3.1–6.4) and 4.2 months for S-1 (95% CI, 1.5–6.9), with a hazard
ratio (capecitabine/S-1) of 1.0 (95% CI, 0.6–1.6) (Figure 3). The
probability of remaining progression-free at 6 months was 35.8
and 42.2% for the capecitabine and S-1 arms, respectively. The
median TTF was 4.3 months for capecitabine (95% CI, 2.8–5.7)
and 3.0 months for S-1 (95% CI, 1.5–4.5). The median OS was 9.5
months for capecitabine (95% CI, 7.8–11.3) and 8.1 months for
S-1 (95% CI, 4.9–11.4); the hazard ratio (capecitabine/S-1) was
0.9 (95% CI, 0.5–1.4) (Figure 4). The 1-year survival rate was
30.2% for capecitabine and 27.3% for S-1. Cox proportional hazard
analyses found that none of the potential prognostic factors were
statistically significant predictive factors for OS (Table 3). How-
ever, patients who received prior gastrectomy had tendency
towards a longer OS according to both univariate and multivariate
analyses.
Safety
Haematologic and nonhaematologic adverse events are shown
in Table 4. The incidence of severe adverse events was very low
in both treatment groups. With the exception of hand–foot
syndrome and stomatitis, which were more frequently found in the
capecitabine arm, the incidence of grade 2 or worse toxicities was
similar in the two treatment arms.
Table 2 Response rates according to RECIST criteria (ITT and PP populations)
ITT population PP population
Capecitabine (N¼46) S-1 (N¼45) Capecitabine (N¼44) S-1 (N¼45)
INV EIR INV EIR INV EIR INV EIR
Response, n
C R 20 1 1 20 1 1
PR 11 12 11 12 11 12 11 12
SD 19 18 20 18 19 18 20 18
PD 8 10 9 10 8 10 9 10
N A 66 4 4 44 4 4
ORR, n (%) 12 (26.1) 13 (28.9) 12 (27.2) 13 (28.9)
95% CI 13.4–38.8 15.6–42.1 14.1–40.4 15.6–42.1
INV¼investigator assessment; EIR¼external independent review; ORR¼overall response rate; CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease; NA¼not assessable; CI¼confidence interval.
Cycles of S-1
0 1 2 3 4 5 6
S-1
Cycles of capecitabine
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Figure 2 Relative dose intensity (median and standard error) for
capecitabine (solid-line) and S-1 (dotted-line) over treatment cycles.
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sDISCUSSION
This is the first randomised trial of two new oral fluoropyrimi-
dines, capecitabine or S-1, in elderly patients with AGC. Although
this was a phase II study and did not aim to compare the treatment
groups statistically, we could estimate the relative efficacy and
safety of the two drugs. Elderly patients may be the best target
population for this purpose because single-agent chemotherapy
can be a good and safe first-line treatment option for this patient
group and it avoids the compounding effects of other agents if
combination therapy is used. For the assessment of the primary
study end point, ORR, all images were extramurally reviewed and
all responses were confirmed. Both agents met the primary end
point and seemed to have similar activity in elderly patients with
AGC. In the PP population, ORRs of 28.9% with S-1 and 27.2%
with capecitabine were observed. The ORR for capecitabine is
largely consistent with a previous study performed in patients with
AGC (Hong et al, 2004), whereas that for S-1 is somewhat lower
than that observed in Japanese trials (Sakata et al, 1998; Koizumi
et al, 2000), but is better than that observed in a non-Japanese
Asian study (Jeung et al, 2007). Median TTF, TTP and OS were also
very similar for both regimens.
Capecitabine and S-1 were well tolerated and no treatment-
related deaths were reported in this study. Both agents were
minimally myelosuppressive and the most frequent haematological
toxicity was anaemia. Although one episode of febrile neutropenia
occurred in one patient treated with capecitabine, there were no
meaningful differences in haematologic toxicities between the two
treatment arms. The most frequently observed grade 3/4
nonhaematological toxicities were anorexia and asthenia. Although
these toxicities developed in less than 10% of patients, they had a
tendency to become more clinically significant as treatment
progressed. The only notable differences in grade 2 or worse
nonhaematologic adverse events between S-1 and capecitabine
were the greater incidences of hand–foot syndrome and stomatitis
among patients treated with capecitabine. There was a steady
decrease in the relative dose intensity of capecitabine during
treatment caused by treatment delays or dose reductions mostly
because of hand–foot syndrome, whereas that of S-1 remained
steady (Figure 2). Considering these findings, we suggest that a
dose of 1000mgm
 2 two times daily, lower than that recom-
mended, would be appropriate for capecitabine in elderly patients
(Bajetta et al, 2005), whereas the recommended dose of 40mgm
 2
two times daily would be acceptable for S-1. These findings suggest
that dose escalation of S-1 may be possible in younger patients.
The rates of some key adverse events reported with capecitabine
in our study, as well as in other phase II studies performed in
Japan or Korea (Hong et al, 2004; Lee et al, 2004; Hyodo et al,
2006), appear to differ from those reported in phase III
multinational studies (Cassidy et al, 2002; Twelves et al, 2005).
The rates of grade 3 hand–foot syndrome (6–13% in Asian phase
II studies vs 17% in multinational phase III studies) and grade
3/4 diarrhoea (2–5 vs 11–13%) tend to be lower, and the rate of
grade 3/4 neutropenia (0–8 vs 1–2%) similar or higher. These
observations are consistent with the recent work of Haller et al
(2008) who reported regional differences in the tolerability of
fluoropyrimidines. They found that the risk of adverse events was
Table 3 Exploratory analysis of effects of prognostic factors on clinical outcome
Hazard ratio (95% confidence interval)
Overall response Overall survival
Factor Univariate Multivariate Univariate Multivariate
Age, years 470 vs p70 1.4 (0.5–3.6) 1.3 (0.5–3.5) 1.2 (0.7–1.8) 1.2 (0.7–2.0)
ECOG performance status X1 vs 0 1.1 (0.3–3.5) 0.82 (0.2–3.9) 1.4 (0.6–1.9) 1.3 (0.7–2.4)
Peritoneal involvement Yes vs no 2.3 (0.8–6.6) 2.8 (0.9–8.5) 1.5 (0.9–2.6) 1.2 (0.6–2.1)
Liver involvement Yes vs no 0.5 (0.2–1.3) 0.4 (0.2–1.3) 1.5 (1.0–2.5) 1.5 (0.9–2.6)
Charlson comorbidity index X1 vs 0 0.9 (0.3–2.5) 1.0 (0.3–2.9) 1.3 (0.8–2.1) 1.1 (0.7–1.8)
Gastrectomy Yes vs no 1.2 (0.4–3.3) 0.9 (0.3–2.8) 0.6* (0.4–1.0) 0.6* (0.3–1.0)
Elevated alkaline phosphatase Yes vs no 1.2 (0.4–3.5) 1.7 (0.5–5.6) 1.0 (0.6–1.8) 0.9 (0.5–1.6)
Treatment X vs S 0.9 (0.4–2.4) 1.4 (0.5–4.1) 1.0 (0.6–1.6) 0.9 (0.6–1.5)
*P¼0.055 and P¼0.07.
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Figure 3 Time-to-progression curves for patients with advanced gastric
cancer treated with capecitabine (solid-line) and S-1 (dotted-line).
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Figure 4 Overall survival curves for patients with advanced gastric
cancer treated with capecitabine (solid-line) and S-1 (dotted-line).
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slowest in patients from East Asian centres, except for grade 3/4
neutropenia, which was most likely to occur in patients from East
Asia. No safety data regarding S-1 monotherapy from the United
States or Europe are yet available.
According to recent SEER data from the United States, 65.5% of
gastric cancers are diagnosed in patients older than 65 years: the
median age at diagnosis of gastric cancer was 71 years and the
median age of gastric cancer-related death was 74 years (Ries et al,
2007). However, because elderly patients are generally excluded
from cancer chemotherapy clinical trials, data to guide the
treatment of older patients with AGC in an evidence-based fashion
are lacking (Lewis et al, 2003; Murthy et al, 2004; Trumper et al,
2006; Lichtman et al, 2007b). The recently reported SPIRITS trial
and a meta-analysis on first-line chemotherapy in patients with
AGC demonstrated a statistically significant benefit in OS for
5-FU-based combination chemotherapy compared with single-
agent chemotherapy (Wagner et al, 2006; Koizumi et al, 2008).
Trumper et al (2006) suggested that elderly (X70 years) patients
without significant co-morbidities should be treated with the same
regimens as younger patients with AGC based on a retrospective
review of three UK multicentre randomised trials. However,
the SPIRITS trial only involved patients of less than 75 years,
and extrapolation of the results from retrospective reviews or
meta-analyses to the elderly patients must be done with caution
because of the following limitations: (1) a small, approximately
1-month, survival advantage observed in the meta-analysis was
achieved at the expense of increased toxicity (Wagner et al, 2006);
(2) chemotherapy-related toxicities, such as neutropenia, anaemia,
stomatitis and diarrhoea, occurred more frequently in the elderly
(Trumper et al, 2006); (3) the early drop out rate was significantly
higher and 5-FU dose intensity was significantly lower in the
elderly when treated with combination chemotherapy containing
5-FU and cisplatin (Trumper et al, 2006); and (4) QOL, which
could be impaired as the intensity of chemotherapy increases, has
not been studied sufficiently. Ideally, standard treatment of AGC in
elderly patients should not be based solely on retrospective subset
analyses of prospective trials, and elderly specific trials are needed
to define the optimal treatment for these patients (Perrone et al,
2002; Jatoi et al, 2005). Considering the ORR, OS and safety results,
our study provides evidence that elderly patients with AGC could
benefit from capecitabine or S-1 monotherapy with minimal
adverse events.
In conclusion, our study indicates that both capecitabine and
S-1 are safe, well tolerated and efficacious in older patients
with AGC. Oral agents, such as capecitabine or S-1, may have
particular appeal in the management of cancer in this patient
population. An additional trial is needed to clarify the potential
predictive factors for drug selection and to establish the effective-
ness of various combinations, including molecular targeted agents,
in older patients with AGC.
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